Stellar Biotechnologies to Present at 2015 Marcum MicroCap Conference

PORT HUENEME, CA--(Marketwired - May 27, 2015) - Stellar Biotechnologies, Inc. ("Stellar" or the "Company") (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced that Company executives will present at the 2015 Marcum MicroCap Conference, being held May 27-28, 2015 at the Grand Hyatt in New York City, NY.

Stellar Biotechnologies Presentation Details
Date: Thursday, May 28, 2015
Time: 9:00-9:30 AM ET
Location: Grand Hyatt New York, Park Avenue at Grand Central, NYC

Frank Oakes, President and CEO of Stellar, and Mark McPartland, VP of Corporate Development and Communications, will present at the event and will be available during the conference for one-on-one meetings. Members of the investment community who are interested in meeting with Stellar's management team during the conference event should contact Marcum MicroCap Conference coordinators to arrange an appointment.

Stellar's presentation will also be webcast live at: http://wsw.com/webcast/marcum3/sbotf. Please register for the webcast at least 10 minutes prior to the start of the presentation to ensure timely access. The webcast and presentation will also be archived for 90 days after the conference on the Company's website at http://ir.stellarbiotechnologies.com/events-calendar. 

For Marcum MicroCap conference information visit: http://www.marcumllp.com/MicroCap
Download the conference app at: http://www.marcumllp.com/MicroCap/download-app

About 2015 Marcum MicroCap Conference
The Marcum MicroCap Conference is dedicated to providing a forum where publicly traded companies under $500 million in market capitalization can network with the investment community. The conference features presentations by CEOs and CFOs from six principal industry sectors, expert panels moderated by industry leaders, and the opportunity to meet with management of these companies.

About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX VENTURE: KLH) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's, and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

Visit www.stellarbiotech.com and the Stellar KLH knowledge base www.klhsite.org.

Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in strategy or development plans; governmental regulations and the ability or failure to comply with governmental regulations; the timing of anticipated results; and other factors referenced in the Company's filings with securities regulators. For a discussion of further risks and uncertainties related to the Company's business, please refer to the Company's public company reports filed with the TSX Venture Exchange and the U.S. Securities and Exchange Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the information contained in this press release.